Jennison Associates appeared to be the Corporate Investor, which was created in 1969. The main office of represented Corporate Investor is situated in the New York. The company was established in North America in United States.
Besides them, we counted 21 critical employees of this fund in our database.
Among the most popular portfolio startups of the fund, we may highlight Avanir Pharmaceuticals, Allogene Therapeutics, Afferent Pharmaceuticals. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Medical Device, Life Science. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager.
The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the Jennison Associates, startups are often financed by Domain Associates, OrbiMed, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Fidelity Management and Research Company, RA Capital Management. In the next rounds fund is usually obtained by Silicon Valley Bank, Oxford Finance LLC, HBM Healthcare Investments AG.
Comparing to the other companies, this Jennison Associates performs on 66 percentage points more the average number of lead investments. The fund is constantly included in less than 2 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2015. The top amount of exits for fund were in 2015.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Anhui Transportation Holding Group | Anhui, China, Hefei |
| Arcview Collective Fund | California, San Francisco, United States |
| Blackstone Life Sciences | Cambridge, Massachusetts, United States |
| Canon Marketing Japan | Japan, Tokyo |
| CRISIL | India, Maharashtra, Mumbai |
| Exnetwork Capital | - |
| GuarantCo | - |
| HALLMANN HOLDING International Investment GmbH | - |
| Hercules Capital, Inc. | California, Palo Alto, United States |
| IFC InfraVentures | District of Columbia, United States, Washington |
| Long Pinxi Capital | - |
| MSD Partners | New York, New York, United States |
| Novelion Therapeutics | British Columbia, Canada, Vancouver |
| Scheer Partners Investments | Maryland, Rockville, United States |
| Shalamuka Capital | Gauteng, NA - South Africa, South Africa |
| The JumpFund | Chattanooga, Tennessee, United States |
| TrueBridge Capital Partners | Chapel Hill, North Carolina, United States |
| Zimi Fund | China, Shanghai |
Albert Kwok Managing Director, Portfolio Manager 46a0700a3b6ca 8b4dd53bcfea26f6808dd7a4d61f7feb a0c578d8 5481418830fd23539b724fdb4eda875a b1b154c0f148 d282636008d0fe4309b54c2aebb00d48 87b854f0ed6 5481418830fd23539b724fdb4eda875a 597f1593f0881 8a295eb2beca4c7fcab0b0363e1b0152 
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Syndax Pharmaceuticals | $80M | 24 Aug 2015 | Massachusetts, United States | ||
Wave Life Sciences | $66M | 18 Aug 2015 | Boston, Massachusetts, United States | ||
Ovid Therapeutics | $75M | 11 Aug 2015 | New York, New York, United States | ||
Editas Medicine | $120M | 10 Aug 2015 | Cambridge, Massachusetts, United States | ||
GenSight Biologics | $36M | 23 Jul 2015 | Paris, Ile-de-France, France | ||
Afferent Pharmaceuticals | $55M | 08 Jul 2015 | California, United States | ||
UNUM Therapeutics | $65M | 11 Jun 2015 | Cambridge, Massachusetts, United States | ||
Dimension Therapeutics | $65M | 21 Apr 2015 | Cambridge, Massachusetts, United States | ||
Aeglea BioTherapeutics | $44M | 23 Mar 2015 | Austin, Texas, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Syndax Pharmaceuticals | $80M | 24 Aug 2015 | Massachusetts, United States | ||
Wave Life Sciences | $66M | 18 Aug 2015 | Boston, Massachusetts, United States | ||
Ovid Therapeutics | $75M | 11 Aug 2015 | New York, New York, United States | ||
Editas Medicine | $120M | 10 Aug 2015 | Cambridge, Massachusetts, United States | ||
GenSight Biologics | $36M | 23 Jul 2015 | Paris, Ile-de-France, France | ||
Afferent Pharmaceuticals | $55M | 08 Jul 2015 | California, United States | ||
UNUM Therapeutics | $65M | 11 Jun 2015 | Cambridge, Massachusetts, United States | ||
Dimension Therapeutics | $65M | 21 Apr 2015 | Cambridge, Massachusetts, United States | ||
Aeglea BioTherapeutics | $44M | 23 Mar 2015 | Austin, Texas, United States |
